Stocks · News reference
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Eli Lilly has entered an agreement with telehealth platform Hims & Hers Health to offer its obesity medications Zepbound and Foundayo directly on the platform, intensifying competition with Novo Nordisk's existing presence on the site.
The Ozempic market is projected to grow from USD 30.04 billion in 2026 to USD 113.95 billion by 2032, with a CAGR of 24.89%. Growth is driven by expanding diabetes treatment demand, broader metabolic health applications, and increasing adoption of GLP-1 therapies. North America leads the market, while Asia-Pacific emerges as a significant growth region. Key challenges include treatment affordability, reimbursement restrictions, and supply-chain requirements.
Aligos Therapeutics released its Q3 2026 financial results, noting a narrowed operating loss and cash runway projections.
Aligos Therapeutics reported positive data from five presentations at the AASLD's The Liver Meeting 2026, highlighting advancements in its pipeline for liver and viral diseases.
Perspective Therapeutics reported positive incremental data from its Phase 1/2a trial of [212Pb]VMT-α-NET in patients with SSTR2-expressing neuroendocrine tumors, with plans for an end-of-Phase 2 meeting in early 2027.
Bernstein Research has updated its outlook on Novo Nordisk, raising the price target while maintaining an 'Underperform' rating.